Prevention of macrovascular complications

European Heart Journal, Supplement

Volumn 5, Issue B, 2003, Pages

  Fisher, M ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Blood glucose control; Cardiovascular risk; Diabetes mellitus; Hyperlipidaemia; Hypertension

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; AMLODIPINE; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROPAMIDE; CHLORTALIDONE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FIBRIC ACID DERIVATIVE; FOSINOPRIL; GLIBENCLAMIDE; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; LOSARTAN; METFORMIN; NISOLDIPINE; NITRENDIPINE; RAMIPRIL; RESERPINE; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; UNINDEXED DRUG;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DRUG MECHANISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN TREATMENT; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION;

EID: 0037234298     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90037-X     Document Type: Article

References (40)

1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974; 23: 105-11.
2. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Cause-specific mortality in a population with diabetes. South Tees Diabetes Mortality Study. Diabetes Care 2002; 25: 43-8.
3. Fisher M, Shaw K. Diabetes: a state of premature cardiovascular death. Practical Diabetes Int 2001; 18: 183-4.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
5. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
6. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Athersclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-10.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
9. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes mellitus II. Mortality results. Diabetes 1970; 19(suppl 2): 789-830.
10. Stratton IM, Adler AI, Neil HAW, et al., on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications on type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
11. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-6.
12. Haffner SM, Greenberg AS, Weston WM, Chen H, Freed MI. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabete mellitus. Circulation 2002; 106: 679-84.
13. Holman RR, Cull CA, Turner RC, on behalf of the UKPDS Study Group. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycaemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-4.
14. Chiasson J-L, Josse RG, Gomis R, et al., for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7.
15. Hanefeld M, Temelkova-Kurktschiev T, on behalf of the STOP-NIDDM Trial Research Group. Acarbose reduces incidence of type 2 diabetes and of myocardial infarction in subjects with impaired glucose tolerance: the STOP-NIDDM trial. Eur Heart J 2002; 4(suppl): 609.
16. Adler AI, Stratton IM, Neil AHW, et al., on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36); prospective observational study. BMJ 2000; 321: 412-9.
17. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
18. Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319: 630-5.
19. Ramsay LE, Williams B, Johnston GD, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-92.
20. Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R, on behalf of the Societies. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 20(suppl 2): S1-29.
21. Curb JD, Pressel SL, Cutler JA, et al., for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-92.
22. Tuomilehto J, Rastenyte D, Birkenhager WH, et al., for the Systolic Hypertension in Europe Trail Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84.
23. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
24. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
25. Barzilay JI, Jones CL, Davis BR, for the ALLHAT Collaborative Research Group. Baeline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2001; 24: 654-8.
26. Dahlof B, Devereux RB, Kjeldsen S, et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
27. Lindholm LH, Ibsen H, Dahlof B, et al., for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.
28. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20.
29. Goldberg RB, Mellies MJ, Sacks FM, et al. for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998; 98: 2513-9.
30. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
32. Colhoun HM, Thomson MJ, Mackness MI, for the CARDS Investigators. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabetes Med 2002; 19: 201-11.
33. Rubins HB, Robins SJ, Collins D, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
34. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 398: 81-106.
35. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
36. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-8.
37. Gerstein HC, Bosch J, Pogue J, Wayne Taylor D, Zinman B, Yusuf S, the HOPE Study Investigators. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Diabetes Care 1996; 19: 1225-8.
38. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 200; 355: 253-9.
39. Kenny C. Primary care prevention of cardiovascular disease in diabetes. Practical Diabetes Int 2001; 18: 212-6.
40. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002; 324: 1577-80.